Skip to main content

Table 2 In vitro activity of 9 generic products of oxacillin and the innovator against two strains of S. aureus.

From: In vitro and in vivo comparison of the anti-staphylococcal efficacy of generic products and the innovator of oxacillin

OXACILLIN (OXA) PRODUCTS S. aureusATCC 29213 S. aureusGRP-0057
  MIC (mg/L) MBC (mg/L) MBC/MIC Ratio MIC (mg/L) MBC (mg/L) MBC/MIC Ratio
OXA-BMS (innovator) 0.22 0.40 1.78 0.16 0.25 1.59
OXA-BLA 0.50 0.50 1.00 0.18 0.50 2.83
OXA-CAR 0.50 1.00 2.00 0.50 0.50 1.00
OXA-COL 0.50 0.71 1.41 0.18 0.35 2.00
OXA-MEM 0.13 0.13 1.00 0.13 0.13 1.00
OXA-OPH 0.25 0.71 2.83 0.18 0.25 1.41
OXA-PEN 0.25 0.35 1.41 0.18 0.21 1.19
OXA-QIM 0.50 1.00 2.00 0.18 0.25 1.41
OXA-SER 0.25 0.50 2.00 0.25 0.50 2.00
OXA-VIT 0.13 0.13 1.00 0.13 0.13 1.00
Exact P (KW*) 0.2115 0.2110 0.2611 0.3650 0.1339 0.2751
  1. Values represent geometric means of each MIC, MBC and MBC/MIC ratio, obtained from 1 to 3 duplicate determinations (ranges not included for brevity and clarity). * Kruskal-Wallis test.